Wegovy

What is Wegovy?

Wegovy is a prescription injectable medication containing semaglutide — the same active ingredient as Ozempic — but dosed at higher levels and specifically FDA-approved for chronic weight management. Manufactured by Novo Nordisk, Wegovy received initial FDA approval on June 4, 2021, under new drug application number 215256 for adults with obesity or overweight with at least one weight-related comorbidity. The label was expanded in June 2022 to include adolescents aged 12 and older. In March 2024 the FDA added a cardiovascular risk-reduction indication for adults with established cardiovascular disease who are overweight or obese, based on the SELECT trial. In December 2025 the FDA approved an oral Wegovy tablet as an alternative to the injection. In March 2026 the FDA approved Wegovy HD, a higher-dose formulation reaching 7.2 mg weekly, under the Accelerated Approval Pathway. Wegovy is among the most prescribed weight-management medications in the United States and has become culturally synonymous with the modern GLP-1 weight-loss era.

How Wegovy works

Wegovy works by mimicking the natural incretin hormone GLP-1 (glucagon-like peptide-1). Semaglutide binds the GLP-1 receptor and produces four coordinated effects: it stimulates glucose-dependent insulin release from the pancreas, suppresses glucagon, slows gastric emptying so meals feel more filling longer, and acts on appetite-regulating neurons in the hypothalamus to reduce hunger and food-reward signals. The combination reduces caloric intake by roughly 30 percent in trial populations without conscious dieting. Semaglutide's engineered albumin binding and modified peptide backbone give it a half-life of approximately seven days, supporting once-weekly dosing. Wegovy reaches steady-state concentration at each dose step after four to five weeks, which is why the titration schedule is paced in four-week increments. The higher maintenance doses in Wegovy (2.4 mg, and now up to 7.2 mg in Wegovy HD) produce stronger appetite suppression and steeper weight loss than the 2 mg maximum approved for Ozempic. Beyond appetite, semaglutide also appears to shift food-reward circuitry: in functional imaging studies, patients on semaglutide report reduced cravings for calorie-dense foods and a diminished pleasure response to high-fat and high-sugar items, which helps explain why sustained weight loss is achievable without counting calories.

Who Wegovy is for

Wegovy is FDA-approved for adults and adolescents who meet specific BMI and comorbidity criteria:

• Adults with obesity (BMI ≥ 30 kg/m²) — as an adjunct to reduced-calorie diet and increased physical activity.
• Adults with overweight (BMI ≥ 27 kg/m²) who also have at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea.
• Adolescents aged 12 and older with BMI at the 95th percentile or greater for age and sex.
• Adults with established cardiovascular disease (prior heart attack, stroke, or symptomatic peripheral artery disease) who are overweight or obese — to reduce the risk of major adverse cardiovascular events. This indication was added in March 2024 based on the SELECT trial.

Wegovy is not approved for type 2 diabetes on its own (Ozempic is the semaglutide product for diabetes) and is not recommended during pregnancy or breastfeeding. Insurance coverage for Wegovy is notoriously variable — many commercial plans and most Medicare Part D plans exclude coverage for weight-loss medications, though the new cardiovascular indication has started to open coverage for some patients with documented heart disease.

How to take Wegovy

Wegovy is administered as a subcutaneous injection once weekly using a pre-filled, single-dose auto-injector pen. The injection can be given in the abdomen, thigh, or upper arm, at any time of day, with or without food. Rotate the injection site with each dose to reduce the risk of lipohypertrophy. Each pen is used once and then discarded in a sharps container; never reuse needles or share pens between individuals.

The standard titration schedule steps up monthly: 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, then 1 mg for four weeks, then 1.7 mg for four weeks, then the maintenance dose of 2.4 mg weekly. This slow ramp is specifically designed to reduce gastrointestinal side effects, which are sharpest at each dose increase. Wegovy HD extends the titration further: after maintaining at 2.4 mg, patients may escalate to 3.6 mg for four weeks and finally 7.2 mg weekly, with the higher doses typically reserved for patients who have not achieved target weight loss at 2.4 mg or who are transitioning from another GLP-1 agent.

If you miss a dose and the next scheduled dose is more than two days (48 hours) away, take the missed dose as soon as possible. If the next dose is less than two days away, skip the missed dose and resume your regular schedule. Do not take two doses within a 48-hour window. Store unopened pens in the refrigerator between 36°F and 46°F (2-8°C). After first use, a pen can stay at room temperature (up to 86°F / 30°C) for up to 28 days, then discard.

Side effects of Wegovy

The Wegovy side-effect profile is the same in kind as Ozempic but generally more pronounced in frequency and intensity because of the higher doses. All frequencies below come from the STEP clinical trial program pooled data reported in the FDA prescribing information.

Common side effects (worst during titration, usually improving by month 3-4):

• Nausea — reported in approximately 44 percent of patients, peaking during dose escalation to 1 mg and 1.7 mg
• Diarrhea — 30 percent, most frequent in early titration
• Vomiting — 24 percent, more common at higher doses
• Constipation — 24 percent, can persist longer than other GI effects
• Abdominal pain — 20 percent
• Headache — 14 percent
• Fatigue — 11 percent
• Dyspepsia, flatulence, eructation — each in the 5 to 10 percent range

Less common but serious adverse events requiring prompt medical attention:

• Acute pancreatitis (less than 1 percent) — severe upper abdominal pain radiating to the back
• Gallbladder events (cholelithiasis, cholecystitis, about 2.6 percent) — somewhat elevated versus the general population, particularly in patients with rapid weight loss
• Acute kidney injury — secondary to dehydration from persistent GI effects; rare but reported
• Hypoglycemia — risk rises sharply when Wegovy is combined with insulin or sulfonylureas; uncommon on Wegovy alone
• Serious allergic reactions — anaphylaxis and angioedema have been reported post-marketing
• Suicidal ideation or depression — small numbers of reports prompted a 2023 EMA review; current FDA labeling advises monitoring

Management strategies include slowing or pausing titration, eating smaller portions more frequently, avoiding high-fat or spicy foods during dose increases, staying well hydrated, limiting alcohol, and temporarily using OTC anti-nausea products when appropriate. Call your prescriber for severe abdominal pain, persistent vomiting, signs of dehydration, vision changes, chest pain, mood changes, or any rapid new symptom. For patients on Wegovy during active weight loss, preventing muscle loss with resistance training and adequate protein is also worth discussing with your prescriber.

Who should not take Wegovy

Wegovy is contraindicated for patients with any of the following:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide or any Wegovy excipient
• Concurrent use of other semaglutide-containing products (Ozempic, Rybelsus)
• Concurrent use of other GLP-1 receptor agonists

Boxed warning: In rodent studies, semaglutide produces thyroid C-cell tumors including medullary thyroid carcinoma. It is unknown whether semaglutide causes such tumors in humans. Patients should be counseled to report any persistent neck mass, dysphagia, dyspnea, or hoarseness to their prescriber.

Additional caution is appropriate for patients with a history of pancreatitis, severe gastroparesis, significant kidney impairment (dehydration from GI effects can worsen renal function), gallbladder disease, diabetic retinopathy (rapid improvement in glycemia may temporarily worsen retinopathy in the subset of patients with concurrent type 2 diabetes), pregnancy or plans to become pregnant (discontinue at least two months before a planned pregnancy due to semaglutide's long half-life), or breastfeeding. Because Wegovy slows gastric emptying, the absorption of oral medications may be affected — review oral contraceptives, thyroid hormone, warfarin, and time-critical cardiovascular drugs with your pharmacist. Patients taking insulin or a sulfonylurea for type 2 diabetes may need dose reductions to avoid hypoglycemia when Wegovy is added.

What to expect on Wegovy

The Wegovy experience is a slow unlock of appetite changes over the first several months, punctuated by dose-increase days.

Week 1 to week 16 (titration through 1.7 mg). Appetite suppression builds in noticeable steps with each new dose. By week 4 most patients report feeling fuller faster. By week 8 many report not thinking about food between meals. GI side effects peak in the first 3 to 7 days after each dose increase and subside as the body adapts. Weight loss averages 3 to 6 kg during this phase.

Week 17 to month 6 (maintenance at 2.4 mg). This is the phase of steepest weight loss for most patients. In the STEP 1 trial, patients on 2.4 mg weekly lost an average of 9 to 10 percent of baseline body weight by month 6. Blood pressure typically drops, lipid profiles improve, and many patients with prediabetes see normalization of fasting glucose.

Month 6 to month 18. Weight loss continues to accumulate at a decelerating rate. At 68 weeks (roughly 16 months) in STEP 1, mean weight loss was approximately 15.2 kg (16.9 percent of body weight); about half of treated patients lost at least 15 percent. Patients on Wegovy HD who escalate further may see additional incremental weight loss of 1 to 3 kg beyond the 2.4 mg plateau.

Beyond 18 months and on to the long term. The SELECT cardiovascular outcomes trial followed patients for a median of 3.3 years and showed a 20 percent reduction in major adverse cardiovascular events sustained over years. Patients who discontinue Wegovy typically regain two-thirds of lost weight within one year, which is why chronic continuous treatment is the label-indicated approach. Your prescriber will schedule check-ins every three to six months to monitor weight, cardiometabolic labs, mental health, and tolerability.

Wegovy cost and coverage

The list price of Wegovy is approximately $1,349.02 per pack (four weekly doses) before insurance, based on the Novo Nordisk wholesale acquisition cost. Wegovy HD and the oral formulation are priced similarly. There is no FDA-approved generic version, and Novo Nordisk holds patent protection blocking generic competition until at least 2033.

What you actually pay depends heavily on coverage, and Wegovy coverage is significantly more restrictive than Ozempic:

• Commercial insurance for obesity: Many major plans cover Wegovy for patients with a documented obesity diagnosis and failed attempts at diet and exercise, usually with prior authorization. Copays commonly range from $25 to $300 per month on plans that cover weight-management drugs. Some plans exclude weight-loss drugs entirely.
• Commercial insurance for cardiovascular indication: Coverage improved notably after the SELECT-based indication was added in 2024; plans that previously excluded all weight-loss drugs may cover Wegovy for patients with documented cardiovascular disease.
• Medicare Part D: Currently does not cover Wegovy when prescribed for weight loss alone, as federal law excludes weight-loss medications from Part D coverage. Coverage for the cardiovascular indication is more nuanced — some plans cover it for patients with established heart disease.
• Medicaid: Coverage varies dramatically by state.
• Manufacturer savings: The Novo Nordisk Wegovy Savings Card can reduce eligible commercially-insured patients' copay to as low as $0 per month; not available to Medicare or Medicaid beneficiaries. Terms and cap amounts change periodically.
• NovoCare Pharmacy: Novo Nordisk's direct-to-patient pharmacy offers Wegovy at around $499 per month for cash-pay patients with a valid prescription, bypassing traditional insurance and pharmacy channels.

Check your specific plan's coverage, step-therapy rules, and the current manufacturer savings program before filling — Wegovy coverage terms change more frequently than most medications.